
    
      The study will be an un-blinded, Phase 2, randomized, 1:1, prospective trial comparing
      patients in septic shock receiving norepinephrine and vasopressin followed by phenylephrine
      versus ProvayBlueÂ® as the third-line vasopressor. The third line vasopressor will be compared
      at 1 hour to see if it affects the patient's mean arterial blood pressure (MAP).
    
  